Microbiology International

800ezmicro.com

Microbiology International specializes in autoclaves, peristaltic pumps, air samplers, anaerobic chambers, plate pourers, media preparators and stomachers as well as other automation equipment used in microbiological laboratories. We also provide laboratories with the most innovative automation equipment as well as the highest quality rapid detection kits and consumable products for pathogen detection available worldwide. Our equipment quickly automates tedious, manual lab processes and when combined with our ability to provide customized culture media products, we are able to make your lab as efficient as possible.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

AGEX THERAPEUTICS RECEIVES STOCK EXCHANGE DEFICIENCY LETTER

AgeX Therapeutics | November 24, 2021

news image

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses d...

Read More

Industrial Impact

INHIBRX RECEIVES FDA ORPHAN-DRUG DESIGNATION FOR INBRX-101 FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY

Inhibrx, Inc. | March 04, 2022

news image

Inhibrx, Inc. a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-101 for the treatment of alpha-1 antitrypsin deficiency, or AATD. "We believe this designation from the FDA acknowledges the significant unmet need for novel therapeutic options in a patient community where the standard of care has not s...

Read More

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

PR Newswire | August 26, 2020

news image

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More

ROCHE LAUNCHES EXOME AND CUSTOM KAPA TARGET ENRICHMENT PORTFOLIO TO EMPOWER CLINICAL RESEARCHERS

Roche | May 13, 2020

news image

KAPA HyperExome is a state-of-the-art whole exome research panel with improved performance over the on-market SeqCap portfolio, providing improved coverage and uniformity. The KAPA Target Enrichment portfolio empowers clinical researchers to process more sa...

Read More
news image

Cell and Gene Therapy

AGEX THERAPEUTICS RECEIVES STOCK EXCHANGE DEFICIENCY LETTER

AgeX Therapeutics | November 24, 2021

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses d...

Read More
news image

Industrial Impact

INHIBRX RECEIVES FDA ORPHAN-DRUG DESIGNATION FOR INBRX-101 FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY

Inhibrx, Inc. | March 04, 2022

Inhibrx, Inc. a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-101 for the treatment of alpha-1 antitrypsin deficiency, or AATD. "We believe this designation from the FDA acknowledges the significant unmet need for novel therapeutic options in a patient community where the standard of care has not s...

Read More
news image

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

PR Newswire | August 26, 2020

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More
news image

ROCHE LAUNCHES EXOME AND CUSTOM KAPA TARGET ENRICHMENT PORTFOLIO TO EMPOWER CLINICAL RESEARCHERS

Roche | May 13, 2020

KAPA HyperExome is a state-of-the-art whole exome research panel with improved performance over the on-market SeqCap portfolio, providing improved coverage and uniformity. The KAPA Target Enrichment portfolio empowers clinical researchers to process more sa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us